Avasimibe can cooperate with a DC-targeting and integration-deficient lentivector to induce stronger HBV specific T cytotoxic response by regulating cholesterol metabolism

• Published in: Antiviral research 2023-08, Vol.216, p.105662-105662, Article 105662
• Main Authors: Ma, Siyuan, Lv, Mengjiao, Chen, Xiaohua, Zang, Guoqing, Tang, Zhenghao, Zhang, Yi, Hu, Weiwei
• Format: Article
• Language: English
• Subjects: Acetyl-CoA acetyltransferase-1; Animals; Antineoplastic Agents; Cholesterol - metabolism; Cytotoxic T lymphocyte; HBV infection; Hepatitis B Core Antigens - genetics; Hepatitis B Surface Antigens - genetics; Hepatitis B virus - physiology; Immunological synapse; Integration-deficient; Mice; Mice, Transgenic
• ISSN: 0166-3542; 1872-9096
• DOI: 10.1016/j.antiviral.2023.105662

We have reported a lentivector which could effectively induce HBV-specific cytotoxic T lymphocytes (CTLs). Avasimibe is an inhibitor of acetyl-CoA acetyltransferase-1 (ACAT1), and has been shown to enhance T lymphocyte cytotoxicity on tumor cells. However, the role of avasimibe in lentivector-induced HBV-specific T cytotoxic response remains unknown. Based on previous study, we constructed an integration-deficient lentivector LVDC-ID-HBV (harboring HBcAg expression), and the in vitro experiments showed that the combination of avasimibe exhibited better efficacy in inducing HBV-specific CTL responses including cell proliferation, production of cytokines, as well as CTL killing activities. Mechanism experiments showed that increasing cell membrane cholesterol levels by MβCD-coated cholesterol or ACAT1 inhibition efficiently promoted TCR clustering, signaling transduction and immunological synapse formation, thereby mediating augmented CTL responses. Nevertheless, the depletion of plasma membrane cholesterol with MβCD led to obviously decreased CTL responses. The avasimibe-mediated strengthened immune effects were also determined in animal experiments and the results were in agreement with those from the in vitro research. In particular, the in vivo CTL killing activities were identified by the CFSE or BV-labeled splenocyte lysis assay. Moreover, the experiments in HBV transgenic mice showed that the LVDC-ID-HBV plus avasimibe group demonstrated the lowest serum HBsAg and HBV DNA levels, as well as the lowest expression of HBsAg and HBcAg in liver tissues. We concluded that the HBV-specific CTL immune responses could be potentiated by avasimibe through regulating plasma membrane cholesterol levels. Avasimibe may be a potential adjuvant for lentivector vaccine against HBV infection. •A DC-targeting and integration-deficient lentivector (LV) was constructed.•Avasimibe (Ava) combined with LV mediated stronger HBV-specific CTL responses.•Ava potentiated CTL response by regulating CD8+ T cell cholesterol metabolism.•Ava may be a potential adjuvant for lentivector vaccine against HBV infection.